Friend or Foe? Locoregional Therapies and Immunotherapies in the Current Hepatocellular Treatment Landscape

Friend or Foe? Locoregional Therapies and Immunotherapies in the Current Hepatocellular Treatment Landscape

Over the last several decades, a number of new treatment options for patients with hepatocellular carcinoma (HCC) have been developed. While treatment decisions for some patients remain clear cut, a large numbers of patients have multiple treatment options, and it can be hard for multidisciplinary t...

Full description

Bibliographic Details
Main Authors: Shamar Young, Jack Hannallah, Dan Goldberg, Tina Sanghvi, Junaid Arshad, Aaron Scott, Gregory Woodhead
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:International Journal of Molecular Sciences
Subjects:
transarterial radioembolization
transarterial chemoembolization
ablation
checkpoint inhibitors
immunotherapies
hepatocellular carcinoma
Online Access:https://www.mdpi.com/1422-0067/24/14/11434

Internet

https://www.mdpi.com/1422-0067/24/14/11434

Similar Items